Search for: "Merck & Company, Inc." Results 61 - 80 of 447
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
17 Jun 2018, 11:55 pm by admin
Merck and Co., Inc., 110 Nev. 762, 878 P.2d 948 (1994) (Public policy demands that the burden of accidental injuries caused by products intended for consumption be placed upon those that market them and be treated as a cost of production against which liability insurance can be obtained). [read post]
22 Mar 2018, 1:23 pm by bcutterlaw
Shortly thereafter Schering-Plough Corporation merged with Merck & Company, Inc., who kept Solis on in his same role for a year before firing him. [read post]
17 Mar 2018, 7:18 am by Howard Bashman
” Nate Raymond of Reuters has a report that begins, “Massachusetts’ top court on Friday opened the door for consumers to sue Merck & Co Inc and other makers of brand-name drugs over injuries blamed not on their own medications but on generic versions of their treatments made by other companies. [read post]
29 Jan 2018, 2:57 am
The French government (represented by the public ‘Atout France’ and the French Ministry of Culture) disputed the registration by a private US company, France.com Inc, of a series of trade marks using the word “France.com”. [read post]
17 Oct 2017, 6:09 pm
  Judge Robinson had concluded that the patent was valid, and applied the test articulated in eBay Inc. v. [read post]
18 Sep 2017, 11:12 am by Tom Lamb
Its ruling is the latest in a series of plaintiff-friendly decisions that misconstrued the Supreme Court’s landmark 2009 ruling in Wyeth Inc. v. [read post]
24 Jun 2017, 9:12 pm by Patent Docs
Paul Jahn of Morrison & Foerster LLP; William Krovatin of Merck & Co., Inc.; and Richard Rainey of Covington & Burling LLP will explore the significant ramifications of the recent U.S. [read post]
16 Jun 2017, 9:44 am by rengler@lawbc.com
    This year's winners and technologies are: Merck & Co., Inc. in Greener Synthetic Pathways -- Letermovir: A Case Study in State-of-the-Art Approaches to Sustainable Commercial Manufacturing Processes in the Pharmaceutical Industry; Amgen Inc. and Bachem in Greener Reaction Conditions -- Green Process for Commercial Manufacture of Etelcalcetide Enabled by Improved Technology for Solid Phase Peptide Synthesis;  The Dow Chemical… [read post]
12 Jun 2017, 3:18 pm by escherer@lawbc.com
    This year's winners and technologies are: Merck & Co., Inc. in Greener Synthetic Pathways - Letermovir: A Case Study in State-of-the-Art Approaches to Sustainable Commercial Manufacturing Processes in the Pharmaceutical Industry Merck’s approach was to design an efficient synthesis as early as possible in the drug Letermovir’s process development. [read post]
8 Feb 2017, 3:09 am by Dennis Crouch
Shell Oil Company, et al., No. 16-713 BPCIA – Notice of Commercial Marketing: Apotex Inc., et al. v. [read post]
16 Jan 2017, 5:44 pm by Dennis Crouch
Shell Oil Company, et al., No. 16-713 BPCIA – Notice of Commercial Marketing: Apotex Inc., et al. v. [read post]
30 Dec 2016, 2:58 pm
The case deals with whether an English letter sent by a German company to a US company based on EU trademark infringement constitutes a groundless threat under the Trade Marks Act 1994.PREVIOUSLY ON NEVER TOO LATENever Too Late 127 [week ending on Sunday 18 December] | Around the IP Blogs | Top-level Property Rights Protection Guideline released in China | CEIPI/EAO Conference--"Copyright Enforcement in the Online World" | More on the Swedish application of GS Media |… [read post]
14 Nov 2016, 9:16 am by Dennis Crouch
King Drug Company of Florence, Inc., et al., No. 15-1055 (antitrust reverse payment – appeal from the 3rd Cir.) 3. [read post]